Aprea Therapeutics Provides ACESOT-1051 Program Update for WEE1 Inhibitor APR-1051: Accelerating and Expanding Enrollment. Clinical Data Presentation Planned for Q4 2026
Go back to Aprea Therapeutics Provides ACESOT-1051 Program Update for WEE1 Inhibitor APR-1051: Accelerating and Expanding Enrollment. Clinical Data Presentation Planned for Q4 2026| Aperture Health, Inc. (NASDAQ: APRE) | Delayed: 0.76 +0.01 (1.33%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $0.75 | 52 Week High | $0.08 | |||
| Open | $0.78 | 52 Week Low | $0.00 | |||
| Day High | $0.78 | P/E | N/A | |||
| Day Low | $0.74 | EPS | $0.00 | |||
| Volume | 79,988 | |||||
